Tag Archives: isavuconazonium sulfate

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Posted on 11, December 2013 by EuropaWire PR Editors

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release →

Posted in Government, Healthcare, Pharma & Biotech, Switzerland

Tagged Barbara Zink, Basilea Pharmaceutica, fungal infections, invasive aspergillosis, Isavuconazole, isavuconazonium sulfate, Peer Nils Schröder, QIDP, Qualified Infectious Disease Product, Ronald Scott, treatment, U.S. FDA, zygomycosis